S SIGHT SCIENCES INC
| Market Cap | $209.64M |
| P/E Ratio | — |
| Forward P/E | -8.86 |
| Dividend Yield | — |
| Beta | 2.43 |
| 52W Range | $2.03 - $9.24 |
| # Hedge Funds | 0 |
| Sector | Healthcare |
| Industry | Medical Devices |
Hedge Fund Ownership
| Investor 0 | % of Portfolio Weight of this stock in the investor's portfolio | Value Total dollar value of the position | Shares Number of shares held | Activity Portfolio change type: New, Increased, Decreased, or Sold |
|---|
Insider Trading
| Insider Name of the company insider who made the trade 40 | Type Purchase (buy) or Sale (sell) | Shares Number of shares traded | Price Price per share at time of transaction | Value Total dollar value of the transaction | Trade Date Date the transaction was executed | Filing Date Date the SEC filing was submitted |
|---|---|---|---|---|---|---|
| Bauerlein AlisonChief Operating Officer | Sale | 25,874 | $3.48 | $90.04K | 02 Apr 2026 | 02 Apr 2026 |
| Badawi DavidChief Technology Officer | Sale | 8,168 | $3.48 | $28.42K | 02 Apr 2026 | 02 Apr 2026 |
| Taylor BrentonEVP, Operations & R&D | Sale | 2,869 | $3.70 | $10.62K | 01 Apr 2026 | 01 Apr 2026 |
| Badawi PaulPresident and CEO | Sale | 29,244 | $3.70 | $108.20K | 01 Apr 2026 | 01 Apr 2026 |
| Rodberg JamesChief Financial Officer | Sale | 2,616 | $6.62 | $17.32K | 16 Jan 2026 | 21 Jan 2026 |
| HAYDEN JEREMY B.Chief Legal Officer | Sale | 6,308 | $6.62 | $41.76K | 16 Jan 2026 | 21 Jan 2026 |
| Badawi PaulPresident and CEO | Sale | 22,362 | $6.62 | $148.04K | 16 Jan 2026 | 21 Jan 2026 |
| Badawi DavidChief Technology Officer | Sale | 4,836 | $6.62 | $32.01K | 16 Jan 2026 | 21 Jan 2026 |
| Badawi DavidChief Technology Officer | Sale | 3,695 | $7.48 | $27.64K | 06 Jan 2026 | 06 Jan 2026 |
| HAYDEN JEREMY B.Chief Legal Officer | Sale | 1,785 | $7.48 | $13.35K | 06 Jan 2026 | 06 Jan 2026 |
| Badawi PaulPresident and CEO | Sale | 11,870 | $7.48 | $88.79K | 06 Jan 2026 | 06 Jan 2026 |
| Taylor BrentonEVP, Operations & R&D | Sale | 619 | $7.48 | $4.63K | 06 Jan 2026 | 06 Jan 2026 |
| Rodberg JamesChief Financial Officer | Sale | 594 | $7.48 | $4.44K | 06 Jan 2026 | 06 Jan 2026 |
| Bauerlein AlisonChief Operating Officer | Sale | 9,647 | $7.48 | $72.16K | 06 Jan 2026 | 06 Jan 2026 |
| Paul BadawiPresident and CEO | Sale | 11,870 | $7.48 | $88.79K | 06 Jan 2026 | 06 Jan 2026 |
| Jeremy B. HaydenChief Legal Officer | Sale | 1,785 | $7.48 | $13.35K | 06 Jan 2026 | 06 Jan 2026 |
| David BadawiChief Technology Officer | Sale | 3,695 | $7.48 | $27.64K | 06 Jan 2026 | 06 Jan 2026 |
| Brenton TaylorEVP, Operations & R&D | Sale | 619 | $7.48 | $4.63K | 06 Jan 2026 | 06 Jan 2026 |
| James RodbergChief Financial Officer | Sale | 594 | $7.48 | $4.44K | 06 Jan 2026 | 06 Jan 2026 |
| Alison BauerleinChief Operating Officer | Sale | 9,647 | $7.48 | $72.16K | 06 Jan 2026 | 06 Jan 2026 |
| Rodberg JamesChief Financial Officer | Sale | 4,405 | $7.82 | $34.45K | 05 Jan 2026 | 06 Jan 2026 |
| Bauerlein AlisonChief Operating Officer | Sale | 10,896 | $7.82 | $85.21K | 05 Jan 2026 | 06 Jan 2026 |
| Badawi DavidChief Technology Officer | Sale | 3,051 | $7.82 | $23.86K | 05 Jan 2026 | 06 Jan 2026 |
| HAYDEN JEREMY B.Chief Legal Officer | Sale | 9,385 | $7.82 | $73.39K | 05 Jan 2026 | 06 Jan 2026 |
| Jeremy B. HaydenChief Legal Officer | Sale | 9,385 | $7.82 | $73.39K | 05 Jan 2026 | 06 Jan 2026 |
| James RodbergChief Financial Officer | Sale | 4,405 | $7.82 | $34.45K | 05 Jan 2026 | 06 Jan 2026 |
| Alison BauerleinChief Operating Officer | Sale | 10,896 | $7.82 | $85.21K | 05 Jan 2026 | 06 Jan 2026 |
| David BadawiChief Technology Officer | Sale | 3,051 | $7.82 | $23.86K | 05 Jan 2026 | 06 Jan 2026 |
| Badawi DavidChief Technology Officer | Sale | 2,914 | $7.43 | $21.65K | 02 Jan 2026 | 06 Jan 2026 |
| Badawi PaulPresident and CEO | Sale | 25,356 | $7.43 | $188.40K | 02 Jan 2026 | 06 Jan 2026 |
| David BadawiChief Technology Officer | Sale | 2,914 | $7.43 | $21.65K | 02 Jan 2026 | 06 Jan 2026 |
| Paul BadawiPresident and CEO | Sale | 25,356 | $7.43 | $188.40K | 02 Jan 2026 | 06 Jan 2026 |
| Encrantz Staffan | Buy | 13,958 | $8.31 | $115.96K | 16 Dec 2025 | 18 Dec 2025 |
| Rodberg JamesChief Financial Officer | Sale | 2,518 | $8.25 | $20.77K | 02 Dec 2025 | 03 Dec 2025 |
| James RodbergChief Financial Officer | Sale | 2,518 | $8.25 | $20.77K | 02 Dec 2025 | 03 Dec 2025 |
| HAYDEN JEREMY B.Chief Legal Officer | Sale | 44,850 | $8.08 | $362.39K | 25 Nov 2025 | 26 Nov 2025 |
| Jeremy B. HaydenChief Legal Officer | Sale | 44,850 | $8.08 | $362.39K | 25 Nov 2025 | 26 Nov 2025 |
| Taylor BrentonEVP, Operations & R&D | Sale | 14,418 | $7.06 | $101.79K | 17 Nov 2025 | 18 Nov 2025 |
| HAYDEN JEREMY B.Chief Legal Officer | Sale | 3,150 | $8.01 | $25.23K | 12 Nov 2025 | 14 Nov 2025 |
| Taylor BrentonEVP, Operations & R&D | Sale | 591 | $3.37 | $1.99K | 06 Oct 2025 | 08 Oct 2025 |
Frequently Asked Questions
What is SGHT stock price today?
SIGHT SCIENCES INC (SGHT) is currently trading at $3.97. The stock has a 52-week range of $2.03 to $9.24 and a market capitalization of $209.64M.
Is SGHT a good stock to buy in 2026?
SIGHT SCIENCES INC has a P/E ratio of N/A (forward P/E: N/A), a dividend yield of none, and 1-year performance of +54.3%. 0 hedge funds hold this stock. Review the fundamentals and ownership data above to make an informed decision.
Are insiders buying or selling SGHT stock?
There have been 40 insider transactions for SGHT in recent months. Insider buys can signal management confidence, while sales may reflect diversification or personal financial planning. Check the Insider Trading section above for details.
How has SGHT stock performed over the past year?
SIGHT SCIENCES INC (SGHT) has returned +54.3% over the past 12 months. The stock traded between $2.03 and $9.24 during this period, and is currently at $3.97.
Which hedge funds own SGHT (SIGHT SCIENCES INC)?
0 tracked hedge funds currently hold SGHT in their portfolios as of the latest 13F filings. See the ownership table above for the complete list.
What is SGHT's market cap and valuation?
SIGHT SCIENCES INC (SGHT) has a market capitalization of $209.64M. The trailing P/E ratio is N/A and forward P/E is N/A. The stock is classified in the Healthcare sector.
What is SGHT's revenue and profitability?
SIGHT SCIENCES INC reported revenue of $77.36M with net income of N/A and a profit margin of N/A. The stock has a beta of 2.43.
What sector is SGHT in and who are its biggest institutional holders?
SIGHT SCIENCES INC (SGHT) operates in the Healthcare sector. It is held by 0 tracked hedge funds. See the ownership table above for the complete list.